Mirum Pharmaceuticals, Inc.
MIRM
Rank in Stocks
#3281
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Share Price
$82.58
Market Cap
$5.36B
Change (1 day)
3.05%
Change (1 year)
12.31%
Country
US
Trade Mirum Pharmaceuticals, Inc. (MIRM)
Category
Healthcare
P/S ratio for Mirum Pharmaceuticals, Inc. (MIRM)
P/S ratio as of October 2026 TTM: 8.40
According to Mirum Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.40. At the end of 2023 the company had a P/S ratio of 6.48.
P/S ratio history for Mirum Pharmaceuticals, Inc. from 2018 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 8.40 | 44.09% |
| 2024 | 5.83 | -9.93% |
| 2023 | 6.48 | -24.37% |
| 2022 | 8.56 | -66.12% |
| 2021 | 25.27 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | 19.31% |
US
|
|
| 40.55 | 382.73% |
US
|
|
| 3.96 | -52.85% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 20.78% |
NL
|
